title: Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
abstract: A superior drug formulation capable of achieving efficient osteogenesis is in imperative demand for the treatment of osteoporosis. In the present study we investigated the potential of using novel risedronate-hydroxyapatite (HA) nanoparticle based formulation in an animal model of established osteoporosis. Nanoparticles of HA loaded with risedronate (NHLR) of various sizes (80-130 nm) were generated for bone targeted drug delivery. Three months after ovariectomy, 36 ovariectomized (OVX) rats were divided into 6 equal groups and treated with various doses of NHLR (500, 350 and 250 microg/kg intravenous single dose) and sodium risedronate (500 microg/kg, intravenous single dose). Untreated OVX and sham OVX served as controls. One month after drug administration, the left tibia and femur were tested for bone mechanical properties and histology, respectively. In the right femur, bone density was measured by method based on Archimedes principle and bone porosity analyses were performed using X-ray imaging. NHLR (250 microg/kg) showed a significant increase in bone density and reduced bone porosity when compared with OVX control. Moreover, NHLR (250 microg/kg) significantly increased bone mechanical properties and bone quality when compared with OVX control. The results strongly suggest that the NHLR, which is a novel nanoparticle based formulation, has a therapeutic advantage over risedronate sodium monotherapy for the treatment of osteoporosis in a rat model of postmenopausal osteoporosis.
authors.affiliation: Department of Pharmacology, Al-Ameen College of Pharmacy, Bangalore 560027, India.
authors.forename: H
authors.initials: H
authors.lastname: Sahana
authors.forename: Deepak Kumar
authors.initials: DK
authors.lastname: Khajuria
authors.forename: Rema
authors.initials: R
authors.lastname: Razdan
authors.forename: D Roy
authors.initials: DR
authors.lastname: Mahapatra
authors.forename: M R
authors.initials: MR
authors.lastname: Bhat
authors.forename: Sarasija
authors.initials: S
authors.lastname: Suresh
authors.forename: R Ramachandra
authors.initials: RR
authors.lastname: Rao
authors.forename: L
authors.initials: L
authors.lastname: Mariappan
mesh_terms: D000327:Adsorption; D000818:Animals; D001696:Biomechanical Phenomena / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology*; D002626:Chemistry, Pharmaceutical; D004195:Disease Models, Animal; D017886:Durapatite / Q000737:chemistry*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005269:Femur / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016062:Porosity; D051381:Rats; D017208:Rats, Wistar; D000068296:Risedronic Acid; D017550:Spectroscopy, Fourier Transform Infrared; D013977:Tibia / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D014961:X-Ray Diffraction
chemical_list: D017886:Durapatite; D000068296:Risedronic Acid; D012968:Etidronic Acid